Theodoros Karantanos, M.D., Ph.D is a Clinical Associate at Boston University School of Medicine. He received his degrees from the University of Athens School of Health Sciences. Dr. Karantanos received additional training as a Medical Oncology Clinical Fellow at Johns Hopkins University Hospital, as a Post-doctoral Research Fellow at Beth Israel Deaconess Medical Center, as an Internal Medicine Resident at Boston University Medical Center, and as a Post-doctoral Research Fellow in MD Anderson Cancer Center. He is board certified by the American Board of Internal Medicine and is a member of the following professional societies: Society of Hematologic Oncology, American Society of Hematology, American Society of Medical Oncology, Science advisory Board, American College of Physicians, Massachusetts Medical Society, Prostate Cancer Foundation, and Athens Medical Association. He is a part of many editorial boards and is a reviewer of many medical journals. Dr. Karantanos has over 40 published original, peer reviewed articles.
- University of Athens, MD
- Published on 10/8/2018
Karantanos T, Rooper L, Kang Y, Lin CT, Wenga P, Sagorsky S, Lauring J, Kang H. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. Oncologist. 2019 Feb; 24(2):146-150. PMID: 30297384.
- Published on 8/1/2018
Rooper LM, Karantanos T, Ning Y, Bishop JA, Gordon SW, Kang H. Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity. Am J Surg Pathol. 2018 Aug; 42(8):1121-1126. PMID: 29683815.
- Published on 6/13/2018
Karantanos T, Karanika S, Seth B, Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol. 2019 Feb; 21(2):206-212. PMID: 29948974.
- Published on 3/30/2018
Karantanos T, Moliterno AR. The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy. Blood Rev. 2018 09; 32(5):426-432. PMID: 29627078.
- Published on 5/23/2017
Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017 May 23; 10(480). PMID: 28536297.
- Published on 5/9/2017
Karantanos T, Politikos I, Boussiotis VA. Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies. Blood Lymphat Cancer. 2017; 7:37-52. PMID: 28701859.
- Published on 2/21/2017
Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep. 2017 02 21; 18(8):1970-1981. PMID: 28228262.
- Published on 2/17/2017
Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: Immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017 May; 8(3):229-235. PMID: 28223073.
- Published on 12/20/2016
Christofides A, Karantanos T, Bardhan K, Boussiotis VA. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget. 2016 Dec 20; 7(51):85624-85640. PMID: 27793053.
- Published on 11/1/2016
Karantanos T, Boussiotis VA. JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function. Transl Cancer Res. 2016 Nov; 5(Suppl 6):S1208-S1211. PMID: 28868240.
View 35 more publications: View full profile at BUMC